Allogene Therapeutics ALLO Change in AP
Change in AP at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayable.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's change in ap.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's change in AP?
- Allogene Therapeutics (ALLO) reported change in AP of $663K in Q1 2026.
- How has Allogene Therapeutics's change in AP changed year-over-year?
- Allogene Therapeutics's change in AP increased by 297.3% year-over-year, from -$336K to $663K.
- What is the long-term trend for Allogene Therapeutics's change in AP?
- Over 3 years (2021 to 2024), Allogene Therapeutics's change in AP has grown at a -11.2% compound annual growth rate (CAGR), from -$767K to -$537K.
- What does change in AP mean?
- Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.